Ann: Appendix 4C - Quarterly, page-7

Botanix Executive Director Matt Callahan: "The September quarter was another extremely productive one for Botanix and we are very pleased with our progress. The clinical development of our portfolio of lead and pipeline products is advancing rapidly, and we are receiving increasing recognition from partners, potential licensees and investors. We are well-placed to maintain our current momentum and look forward to updating the market on further developments."

Hoping for my partially filled order @7.5c to be completed, I don't think it'll stay long at this price.